AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients - Reuters



AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have their tumour surgically removed, trial data showed.